Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma

Technology appraisal guidance
Reference number: TA321
Published: 22 October 2014

History

Review proposal consultation

Review proposal consultation
Stakeholder matrix (PDF 212 KB)

Published:

10 November 2017
Review proposal paper (PDF 276 KB)

Published:

10 November 2017

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: final appraisal determination

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: final appraisal determination information
Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: equality impact assessment
Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: equality impact assessment (PDF 156 KB)

Published:

28 October 2014
Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: evaluation report
Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: evaluation report (PDF 8.02 MB)

Published:

18 September 2014
Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: final appraisal determination document
Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: final appraisal determination document (PDF 335 KB)

Published:

18 September 2014

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: final scope (post referral)

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: final scope (post referral)
Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: final scope (post referral) (PDF 94 KB)

Published:

02 May 2014

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: final matrix

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: final matrix
Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: final matrix (PDF 95 KB)

Published:

02 May 2014

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: response to consultee and commentator comments on the draft scope and provisional matrix (post referral)

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: response to consultee and commentator comments on the draft scope and provisional matrix (post referral)
Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: response to consultee and commentator comments on the draft scope and provisional matrix (post referral) (PDF 209 KB)

Published:

07 May 2014

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: draft scope - (pre referral)

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: draft scope - (pre referral)
Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: draft scope - (pre referral) (PDF 103 KB)

Published:

09 April 2013